STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARCT
  4. [Form 4] Arcturus Therapeutics Holdings Inc. Insider Trading Activity

Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share.

According to the disclosure, the options vest monthly over a one-year period from the grant date, aligning the director’s compensation with the company’s performance over time. All 15,000 options are shown as held directly following this grant, with an expiration date in 2036.

Positive

  • None.

Negative

  • None.
Insider BARLOW JAMES F
Role null
Type Security Shares Price Value
Grant/Award Stock option (right to buy) 15,000 $0.00 --
Holdings After Transaction: Stock option (right to buy) — 15,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 15,000 options Stock option grant to director on June 5, 2026
Exercise price $7.30 per share Stock option exercise price for common stock
Options after transaction 15,000 options Total derivative securities held directly after grant
Option term Expires June 5, 2036 Expiration date of granted stock options
Vesting period 12 months Options vest monthly over one year from grant date
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 7.3000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest monthly financial
"Shares underlying the option vest monthly over a one year period"
Board of Directors financial
"annual grant to the Reporting Person as a member of the Board of Directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BARLOW JAMES F
(Last)(First)(Middle)
C/O ARCTURUS THERAPEUTICS HOLDINGS INC.
10285 SCIENCE CENTER DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Arcturus Therapeutics Holdings Inc. [ ARCT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock option (right to buy)(1)$7.306/05/2026A15,000 (1)06/05/2036Common Stock15,000$0.0015,000D
Explanation of Responses:
1. Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
/s/ Ilan Katz, attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcturus Therapeutics (ARCT) report for James F. Barlow?

Arcturus reported that director James F. Barlow received a grant of 15,000 stock options. These options are part of his 2026 annual board compensation and give him the right to buy Arcturus common shares at a set exercise price in the future.

What is the exercise price of James F. Barlow’s new Arcturus (ARCT) stock options?

The granted stock options have an exercise price of $7.30 per share. This means Barlow can purchase Arcturus common stock at $7.30 if he exercises the options, regardless of the market price at the time of exercise, subject to the vesting schedule.

How do the newly granted Arcturus (ARCT) options to James F. Barlow vest?

The 15,000 stock options vest monthly over a one-year period from the grant date. This structure gradually delivers full ownership of the options across twelve months, encouraging ongoing board service and alignment with the company’s performance throughout the year.

When do James F. Barlow’s Arcturus (ARCT) stock options expire?

The granted stock options are scheduled to expire on June 5, 2036. If Barlow does not exercise the options by this expiration date, they will lapse and no longer give him the right to purchase Arcturus common shares at the stated exercise price.

How many Arcturus (ARCT) derivative securities does James F. Barlow hold after this grant?

Following this grant, Barlow is shown holding 15,000 stock options directly. Each option represents the right to acquire one share of Arcturus common stock, subject to vesting and the $7.30 exercise price, providing equity-based compensation tied to future performance.